%0 Journal Article
%A Koirala, S
%A Borisov, S
%A Danila, E
%A Mariandyshev, A
%A Shrestha, B
%A Lukhele, N
%A Dalcolmo, M
%A Shakya, S R
%A Miliauskas, S
%A Kuksa, L
%A Manga, S
%A Aleksa, A
%A Denholm, J T
%A Khadka, H B
%A Skrahina, A
%A Diktanas, S
%A Ferrarese, M
%A Bruchfeld, J
%A Koleva, A
%A Piubello, A
%A Koirala, G S
%A Udwadia, Z F
%A Palmero, D J
%A Munoz-Torrico, M
%A Gc, R
%A Gualano, G
%A Grecu, V I
%A Motta, I
%A Papavasileiou, A
%A Li, Y
%A Hoefsloot, W
%A Kunst, H
%A Mazza-Stalder, J
%A Payen, M-C
%A Akkerman, O W
%A Bernal, E
%A Manfrin, V
%A Matteelli, A
%A Mustafa Hamdan, H
%A Nieto Marcos, M
%A Cadiñanos Loidi, J
%A Cebrian Gallardo, J J
%A Duarte, R
%A Escobar Salinas, N
%A Gomez Rosso, R
%A Laniado-Laborín, R
%A Martínez Robles, E
%A Quirós Fernandez, S
%A Rendon, A
%A Solovic, I
%A Tadolini, M
%A Viggiani, P
%A Belilovski, E
%A Boeree, M J
%A Cai, Q
%A Davidavičienė, E
%A Forsman, L D
%A De Los Rios, J
%A Drakšienė, J
%A Duga, A
%A Elamin, S E
%A Filippov, A
%A Garcia, A
%A Gaudiesiute, I
%A Gavazova, B
%A Gayoso, R
%A Gruslys, V
%A Jonsson, J
%A Khimova, E
%A Madonsela, G
%A Magis-Escurra, C
%A Marchese, V
%A Matei, M
%A Moschos, C
%A Nakčerienė, B
%A Nicod, L
%A Palmieri, F
%A Pontarelli, A
%A Šmite, A
%A Souleymane, M B
%A Vescovo, M
%A Zablockis, R
%A Zhurkin, D
%A Alffenaar, J-W
%A Caminero, J A
%A Codecasa, L R
%A García-García, J-M
%A Esposito, S
%A Saderi, L
%A Spanevello, A
%A Visca, D
%A Tiberi, S
%A Pontali, E
%A Centis, R
%A D'Ambrosio, L
%A van den Boom, M
%A Sotgiu, G
%A Migliori, G B
%T Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort.
%D 2021
%U https://hdl.handle.net/10668/26663
%X The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline (and/or delamanid)- containing regimens in a large cohort of consecutive TB patients treated globally. This observational, prospective study is based on data collected and provided by Global Tuberculosis Network (GTN) centres and analysed twice a year. All consecutive patients (including children/adolescents) treated with bedaquiline and/or delamanid were enrolled, and managed according to WHO and national guidelines. Overall, 52 centres from 29 countries/regions in all continents reported 883 patients as of January 31st 2021, 24/29 countries/regions providing data on 100% of their consecutive patients (10-80% in the remaining 5 countries). The drug-resistance pattern of the patients was severe (>30% with extensively drug-resistant -TB; median number of resistant drugs 5 (3-7) in the overall cohort and 6 (4-8) among patients with a final outcome). For the patients with a final outcome (477/883, 54.0%) the median (IQR) number of months of anti-TB treatment was 18 (13-23) (in days 553 (385-678)). The proportion of patients achieving sputum smear and culture conversion ranged from 93.4% and 92.8% respectively (whole cohort) to 89.3% and 88.8% respectively (patients with a final outcome), a median (IQR) time to sputum smear and culture conversion of 58 (30-90) days for the whole cohort and 60 (30-100) for patients with a final outcome and, respectively, of 55 (30-90) and 60 (30-90) days for culture conversion. Of 383 patients treated with bedaquiline but not delamanid, 284 (74.2%) achieved treatment success, while 25 (6.5%) died, 11 (2.9%) failed and 63 (16.5%) were lost to follow-up.
%K Bedaquiline
%K Delamanid
%K MDR-TB
%K Prevention of TB sequelae
%K Treatment outcomes
%K Tuberculosis
%~